A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: Rationale and design

Tropical Medicine and International Health

Volumn 10, Issue 12, 2005, Pages 1219-1228

  Acosta, Camilo J ^a   Galindo, Claudia M ^a   Ali, Mohammad ^a   Elyazeed, Remon Abu ^b,c   Ochiai, R Leon ^a   Danovaro Holliday, M Carolina ^a   Page, Anne Laure ^a   Thiem, Vu Dinh ^d   Jin, Yang ^e   Park, Jin Kyung ^a   Lee, Hyejon ^a   Puri, Mahesh K ^a   Ivanoff, Bernard ^a,f   Agtini, Magdarina D ^g   Soeharno, Rooswanti ^g   Simanjuntak, Cyrus H ^g   Punjabi, Narain H ^h   Canh, Do Gia ^d   Sur, Dipika ⁱ   Nizami, Qamaruddin ^j   Manna, Byomkesh ⁱ   Bai Qing, Dong ^e   Anh, Dang Due ^d   Honghui, Yang ^e   Bhattacharya, Sujit Kumar ⁱ   Bhutta, Zulfikar ^j   Trach, Dang Duc ^d   Xu, Zhi Yi ^a   Pang, Tikki ^f   Donner, Allan ^k   Clemens, John D ^a   more..

^a International Vaccine Institute   (South Korea)

^b Enteric Disease Research Program   (Egypt)

^c GLAXOSMITHKLINE   (Singapore)

^d NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^e GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^h US NAMRU No 2   (Indonesia)

ⁱ NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^j AGA KHAN UNIVERSITY   (Pakistan)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

more..

Author keywords

Effectiveness trial; Typhoid fever; Vi polysaccharide vaccine

Indexed keywords

TYPHOID VACCINE;

DRUG DEVELOPMENT; EFFICIENCY MEASUREMENT; TYPHOID; VACCINATION;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIA; CHILD; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG EFFICACY; EVALUATION; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFANT; INFECTION PREVENTION; LICENSING; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NEWBORN; PILOT STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; TYPHOID FEVER; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHINA; CLUSTER ANALYSIS; DEVELOPING COUNTRIES; HUMANS; INDONESIA; INFANT; MIDDLE AGED; PAKISTAN; PATIENT ACCEPTANCE OF HEALTH CARE; POLYSACCHARIDES, BACTERIAL; POPULATION SURVEILLANCE; PREVALENCE; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VIETNAM;

ASIA; EURASIA;

EID: 29044441936     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2005.01517.x     Document Type: Article

References (28)

1. Acharya IL, Lowe CU, Thapa R et al. (1987) Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report 1315. The New England Journal of Medicine 317, 101-104.
2. Acosta CJ, Galindo CM, Ochiai RL et al. (2004) The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia. Journal of Health, Population, and Nutrition 22, 240-245.
3. Ali M, Rasool S, Park JK et al. (2004) Use of satellite imagery in constructing a household GIS database for health studies in Karachi, Pakistan. International Journal of Health Geographies 3, 20.
4. Alonso PL, Smith T, Schellenberg JR et al. (1994) Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344, 1175-1181.
5. AMMP (1997) Overview of Census and Verbal Autopsy Methods. Ministry of Health, Tanzania. Report No.: 8.
6. Clemens JD (2003) Thinking downstream to accelerate the introduction of new vaccines for developing countries. Vaccine 21, S2-114-S2-115.
7. Clemens J, Brenner R, Rao M, Tafari N & Lowe C (1996) Evaluating new vaccines for developing countries. Efficacy or effectiveness? The Journal of The American Medical Association 275, 390-397.
8. Crump JA, Luby SP & Mintz ED (2004) The global burden of typhoid fever 1380. Bulletin of the World Health Organization 82, 346-352.
9. DeRoeck D, Clemens JD, Nyamete A & Mahoney RT (2005) Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23, 2762-2774.
10. Donner A & Klar N (2000) Design and Analysis of Cluster Randomization Trials in Health Research 108. Oxford University Press, London.
11. Donner A & Klar N (2002) Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 21, 2971-2980.
12. Donner A, Piaggio G & Villar J (2001) Statistical methods for the meta-analysis of cluster randomization trials 1356. Statistical Methods in Medical Research 10, 325-338.
13. EU, MHLW & FDA (1997) International Conference on Harmonization Guideline for Good Clinical Practice 112. http:// www.emea.eu.int/pdfs/human/ ich/013595en.pdf [accessed 15 June 2005].
14. Germanier R & Fuer E (1975) Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine 1364. The Journal of Infectious Diseases 131, 553-558.
15. Hall AJ & Aaby P (1990) Tropical trials and tribulations. International Journal of Epidemiology 19, 777-781.
16. Hayes RJ, Alexander ND, Bennett S & Cousens SN (2000) Design and analysis issues in cluster-randomized trials of interventions against infectious diseases 1355. Statistical Methods in Medical Research 9, 95-116.
17. Hayes RJ & Bennett S (1999) Simple sample size calculation for cluster-randomized trials 1361. International Journal of Epidemiology 28, 319-326.
18. Kaljee LM, Pack R, Pach A, Nyamete A & Stanton BF (2004) Sociobehavioural research methods for the introduction of vaccines in the diseases of the most impoverished programme. Journal of Health, Population, and Nutrition 22, 293-303.
19. Klugman KP, Koornhof HJ, Robbins JB & Le Cam NN (1996) Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization 47. Vaccine 14, 435-438.
20. Lin FY, Vo AH, Phan VB et al. (2000) The epidemiology of typhoid fever in the Dong Thap province, Mekong Delta region of Vietnam 467. The American Journal of Tropical Medicine and Hygiene 62, 644-648.
21. Robbins JD & Robbins JB (1984) Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi 1327. The Journal of Infectious Diseases 150, 436-449.
22. Sinha A, Sazawal S, Kumar R et al. (1999) Typhoid fever in children aged less than 5 years 281. Lancet 354, 734-737.
23. Wain J & Kidgell C (2004) The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever 1430. Transactions of The Royal Society of Tropical Medicine and Hygiene 98, 423-430.
24. Wang ZG, Zhou WZ & Shi J (1997) Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine 1318. Zhonghua Liu Xing Bing Xue Za Zhi 18, 26-29.
25. WHO (2003) Background Document: The Diagnosis, Treatment and Prevention of Typhoid Fever 1319. WHO/V&B/03.07. http://www.who.int/vaccine_research/ documents/en/ typhoid_diagnosis.pdf [accessed 15 June 2005].
26. WMA (2002) The Declaration of Helsinki 111. http:// www.wmq.net/e/policy/ b3.htm [accessed 15 June 2005].
27. Yang HH, Wu CG, Xie GZ et al. (2001) Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China 11. Bulletin of the World Health Organization 79, 625-631.
28. Yang J, Acosta CJ, Si GA et al. (2005) A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi: expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial. DMC Public Health 5, 1-9.